From access to adherence: the challenges of antiretroviral treatment
| dc.contributor.author | Hardon, Anita | |
| dc.contributor.author | Davey, Sheila | |
| dc.contributor.author | Gerrits, Trudie | |
| dc.contributor.author | Hodgkin, Catherine | |
| dc.contributor.author | Irunde, Henry | |
| dc.contributor.author | Kgatlwane, Joyce | |
| dc.contributor.author | Kinsman, John | |
| dc.contributor.author | Nakiyemba, Alice | |
| dc.contributor.author | Laing, Richard | |
| dc.date.accessioned | 2022-12-28T08:22:21Z | |
| dc.date.available | 2022-12-28T08:22:21Z | |
| dc.date.issued | 2006 | |
| dc.description.abstract | Since the launch of WHO’s ʹ3 by 5ʹ initiative in 2003, many countries in sub‐Saharan Africa have established national antiretroviral treatment (ART) programmes. Although the WHO target of providing access to ART for 3 million people by 2005 was not achieved, by end‐2005 an estimated 1.3 million people in low‐ and middle‐income countries had access to treatment (about 20% of those estimated to be in need) (WHO and UNAIDS, 2006). By mid‐2005, the WHO target had already been overtaken by an even more ambitious aim. In July 2005, the G8 group of industrialized countries committed to the goal of achieving ʹas close as possible to universal access to treatment for all those who need it by 2010.ʹ (UNAIDS, 2006, G8 Gleneagles Summit, 2005). Nonetheless, the challenges in the region remain great. Health systems are weak, and the target orientation of ART programmes risks an emphasis on initiating people on ART at the expense of ensuring effective use of medicines. As discussed in Chapter 2, extremely high levels of adherence (at least 95%) are needed to ensure positive treatment outcomes and prevent the development of drug‐resistance (Paterson et al., 2000). Up till now, only limited operational research has been carried out to identify adherence problems in resource‐poor settings and to strengthen adherence support (Jaffar et al., 2005; Bennet, Boerma and Brugha, 2006; Kent et al., 2003; Akileswaran et al., 2005; Farmer et al., 2001). Previous studies on adherence to ART in Africa have provided quantitative estimates of adherence and data on clinical outcomes, mainly from experimental settings (Ivers, Kendrick and Doucette, 2005; Coetzee et al., 2004; Orrell et al., 2003; Koenig, Léandre and Farmer, 2004; Gill et al., 2005). A recent review of six of these studies reported that 68%‐99% of patients took at least 95% of their medicines. The authors, Ivers et al., conclude that adherence levels in Africa are high, i.e. comparable to those in industrialized settings. However, Gill and colleagues (2005) and Laurent et al., 2002) stress that there is no room for complacency, noting that adherence rates tend to deteriorate over time. | en_US |
| dc.identifier.citation | Hardon, A., Davey, S., Gerrits, T., Hodgkin, C., Irunde, H., Kgatlwane, J., ... & World Health Organization. (2006). From access to adherence: the challenges of antiretroviral treatment: studies from Botswana, Tanzania and Uganda 2006. World Health Organization. | en_US |
| dc.identifier.isbn | 92 4 156328 1 | |
| dc.identifier.isbn | 978 92 4 156328 4 | |
| dc.identifier.uri | https://nru.uncst.go.ug/handle/123456789/6672 | |
| dc.language.iso | en | en_US |
| dc.publisher | World Health Organization | en_US |
| dc.subject | Access | en_US |
| dc.subject | Adherence | en_US |
| dc.subject | Antiretroviral treatment | en_US |
| dc.title | From access to adherence: the challenges of antiretroviral treatment | en_US |
| dc.title.alternative | Studies from Botswana, Tanzania and Uganda 2006 | en_US |
| dc.type | Book | en_US |